Mediwound Stock Today
| MDWD Stock | USD 16.48 0.28 1.67% |
Performance0 of 100
| Odds Of DistressLess than 7
|
Mediwound is trading at 16.48 as of the 24th of November 2024, a 1.67 percent decrease since the beginning of the trading day. The stock's lowest day price was 16.4. Mediwound has only a 7 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for Mediwound are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of October 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of March 2014 | Category Healthcare | Classification Health Care |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel. Mediwound operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 10.79 M outstanding shares of which 593.04 K shares are now shorted by private and institutional investors with about 18.59 trading days to cover. More on Mediwound
Moving against Mediwound Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Mediwound Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMediwound can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mediwound's financial leverage. It provides some insight into what part of Mediwound's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mediwound (MDWD) is traded on NASDAQ Exchange in USA. It is located in 42 Hayarkon Street, Yavne, Israel, 8122745 and employs 100 people. Mediwound is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 177.82 M. Mediwound conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 10.79 M outstanding shares of which 593.04 K shares are now shorted by private and institutional investors with about 18.59 trading days to cover.
Mediwound currently holds about 10.41 M in cash with (10.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31.
Check Mediwound Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Mediwound is $177.82 Million. 30% of Mediwound outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Mediwound Ownership Details
Mediwound Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jpmorgan Chase & Co | 2024-06-30 | 78.8 K | |
| Northern Trust Corp | 2024-09-30 | 74.4 K | |
| Uniplan Investment Counsel, Inc. | 2024-06-30 | 71.2 K | |
| Dafna Capital Management Llc | 2024-09-30 | 64.5 K | |
| J. Goldman & Co Lp | 2024-09-30 | 59 K | |
| Vanguard Group Inc | 2024-09-30 | 56 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 41.6 K | |
| Legato Capital Management Llc | 2024-09-30 | 39.1 K | |
| Prescott Group Capital Management Llc | 2024-09-30 | 37.8 K | |
| Investors Finance Co Plc | 2024-09-30 | 872.1 K | |
| Rosalind Advisors, Inc. | 2024-09-30 | 628 K |
Mediwound Historical Income Statement
Mediwound Stock Against Markets
Mediwound Corporate Management
| Yaron Adv | General VP | Profile | |
| CPA CPA | Ex Director | Profile | |
| Ofer BSc | Chief Officer | Profile | |
| Hani Luxenburg | Chief Officer | Profile | |
| CWS DPM | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mediwound. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Mediwound Stock refer to our How to Trade Mediwound Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mediwound. If investors know Mediwound will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mediwound listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Revenue Per Share 2.18 | Quarterly Revenue Growth 0.061 | Return On Assets (0.16) | Return On Equity (0.76) |
The market value of Mediwound is measured differently than its book value, which is the value of Mediwound that is recorded on the company's balance sheet. Investors also form their own opinion of Mediwound's value that differs from its market value or its book value, called intrinsic value, which is Mediwound's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mediwound's market value can be influenced by many factors that don't directly affect Mediwound's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mediwound's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mediwound is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mediwound's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.